Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Travere Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 62.46 · gapped above the open, then crossed back over prior close. High/low 65.90 at 4:00 am ET, 61.48 at 1:45 pm ET.
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of TVTX revenue | Skew |
|---|---|---|---|
| LGNDLigand Pharmaceuticals, Inc. | 29.29% | 16.00% | 0.5× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Pursuant to the Ligand License Agreement, we are obligated to pay to Ligand an escalating annual royalty between 15% and 17% of net sales of FILSPARI and any other products containing sparsentan or related compounds, which will impact our potential future profit from the commercialization of FILSPARI in the United States and sparsentan for the treatment of IgAN in the EU as well as sparsentan for the treatment of FSGS, if approved.”
$79M relationship0.5× more of TVTX’s book than LGND’s
basisTVTX fy2025 · closed 2025-12 $491MLGND fy2025 · closed 2025-12 $268M
FILING10-K0001438533-25-000010cik 0001438533
“Catalent Pharma Solutions manufactures FILSPARI and performs primary packaging.”
FILING10-K0001438533-25-000010cik 0001438533
“We distribute our other products, Thiola and Thiola EC, through one direct to patient pharmacy, Eversana, who also provides our comprehensive patient support services in the United States.”
FILING10-K0001438533-25-000010cik 0001438533
“Mission Pharmacal manufactures Thiola and Thiola EC.”
FILING10-K0001438533-25-000010cik 0001438533
“PCI Pharma Services performs secondary packaging and serialization for FILSPARI.”
FILING10-K0001438533-25-000010cik 0001438533
“STA Pharmaceutical Hong Kong Limited manufactures the active pharmaceutical ingredient for FILSPARI.”
FILING10-K0001438533-25-000010cik 0001438533
“Pursuant to the Ligand License Agreement, we are obligated to pay Ligand (and Bristol-Myers Squibb Company ("BMS")) an escalating royalty between 15% and 17% of net sales of sparsentan, with payments due quarterly.”
FILING10-K0001438533-26-000014cik 0001438533
“We are party to a collaboration agreement with PharmaKrysto Limited and their early-stage cystinuria discovery program, whereby we are responsible for funding all research and development expenses for the pre-clinical activities associated with the cystinuria program.”
FILING10-K0001438533-25-000010cik 0001438533
“In the fourth quarter of 2025, our partner Renalys was acquired by and merged into Chugai, and as a result of the acquisition, Chugai gained exclusive rights to develop and commercialize sparsentan in Japan, South Korea, and Taiwan.”
FILING10-K0001438533-26-000014cik 0001438533
“We are also party to license agreements with CSL Vifor and Renalys Pharma, Inc. pursuant to which we are entitled to receive certain payments contingent on the future achievement of specified milestones, and royalty payments based on potential future sales in specified licensed territories.”
FILING10-K0001438533-25-000010cik 0001438533
“We are also party to license agreements with CSL Vifor and Renalys (which was acquired by Chugai in November 2025) pursuant to which we are entitled to receive certain payments contingent on the future achievement of specified milestones, and royalty payments based on potential future sales in specified licensed territories.”
FILING10-K0001438533-26-000014cik 0001438533
“We are also party to license agreements with CSL Vifor and Renalys Pharma, Inc. pursuant to which we are entitled to receive certain payments contingent on the future achievement of specified milestones, and royalty payments based on potential future sales in specified licensed territories.”
FILING10-K0001438533-25-000010cik 0001438533
Watchlist prices, news filtered to it, and its next report on your desk.
Travere Therapeutics, Inc. has 8 disclosed suppliers and 4 disclosed customers. Each one is named in an SEC filing, either Travere Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
TVTX (Travere Therapeutics, Inc.) has 8 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: LGND −0.56%, in healthcare.